Biotechnology Austria-based rare diseases specialist AOP Orphan Pharmaceuticals announced its latest analysis on Besremi (ropeginterferon alfa-2b) in patients with Polycythemia Vera (PV), a rare blood cancer, from its CONTINUATION-PV study presented at the European Hematology Association (EHA) 2021 meeting by Professor Jean-Jacques Kiladjian from the Saint-Louis Hospital & Université de Paris in France. 1 July 2021